Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382151 | 0.84 | SLC6A9 (0.46) | SLC6A9IDO1 | |
| SCHEMBL631785 | 0.68 | SLC6A9 (0.46) | SLC6A9IDO1 | |
| SCHEMBL374765 | 0.66 | SLC6A9 (0.34) | SLC6A9CYP2D6 | |
| SCHEMBL3237792 | 0.63 | DPP4 (0.41) | — | |
| SCHEMBL29244326 | 0.62 | EPHX1 (0.45) | — | |
| SCHEMBL4186582 | 0.61 | SLC6A9 (0.51) | SLC6A9CYP2D6 | |
| SCHEMBL3708922 | 0.61 | SLC6A9 (0.51) | SLC6A9CYP2D6 | |
| SCHEMBL4184530 | 0.61 | SLC6A9 (0.51) | SLC6A9CYP2D6 | |
| SCHEMBL17684426 | 0.60 | OPRL1 (0.37) | IDO1 | |
| SCHEMBL17684422 | 0.60 | OPRL1 (0.37) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-02-02 | — | — | US | disclosed |
| EP-2408778-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI (FR) | 2012-01-25 | — | — | EP | disclosed |
| EP-2396335-A1 | N-[(6-AZABICYCLO[3.2.1]OCT-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010106270-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010092287-A1 | N-[(6-AZABICYCLO[3.2.1]OCT-1-YL)-ARYL-METHYL]-BENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029027-A1 | N-[(6-AZA-BICYCLO[3.2.1]OCT-5-YL)-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, C1S | SLC6A9 1683/4885CYP2D6 54/4885IDO1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.